PDCD1 and melanoma: A triple therapy of the novel anti-PD-1-directed monoclonal antibody spartalizumab in combination with dabrafenib and trametinib was studied in the phase 3 COMBI-I trial (NCT02967692), compared to dabrafenib and trametinib plus placebo, as first-line therapy in patients with BRAFV600E/K-mutant unresectable (stage IIIC) or metastatic (stage IV) melanoma (Table 1) [43].